Deferoxamine in Aneurysmal Subarachnoid Hemorrhage trial

Withdrawn

• Conditions: cerebral spasm; delayed cerebral ischemia; 10007963; 10003184; 10002363

• Registration Number: NL-OMON45310
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

* Male or Female,
* 18-85 years old inclusive,
* subarachnoid hemorrhage diagnosed by CT on admission,
* Randomizable within 72 hours of subarachnoid hemorrhage,
* Saccular intracranial aneurysm proven by cerebral angiography or CTA,
* Surgical or endovascular obliteration is performed,
* Able to obtain written informed consent from patient or surrogate.
* Patients in good clinical grade (WFNS 1-3)

Exclusion Criteria

* Pregnancy, as confirmed by routine urine test on admission,
* Abnormal renal function at time of randomization (GFR <60 mL/min)
* Elevated liver function test at time of randomization (AST > 45 U/L and ALT > 35 U/L.)
* History of liver disease or active liver disease, Active renal disease,
* Hypersensitivity to deferoxamine,
* Patient taking medication not recommended for concomitant use with deferoxamine as per the product label (e.g. high dose vit. C medication).
* Patients not able to complete the study follow-up.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint is the occurrence of DCI and total number of patients with<br /><br>drug related adverse events, especially renal, hepatic or neurologic. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-</p><br>